{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,8]],"date-time":"2026-03-08T22:24:25Z","timestamp":1773008665905,"version":"3.50.1"},"reference-count":26,"publisher":"Wiley","issue":"S1","license":[{"start":{"date-parts":[[2009,2,4]],"date-time":"2009-02-04T00:00:00Z","timestamp":1233705600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecular Nutrition Food Res"],"published-print":{"date-parts":[[2009,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>This was a double\u2010blind, randomised, placebo\u2010controlled study to investigate the pharmacokinetics and safety of<jats:italic>trans<\/jats:italic>\u2010resveratrol. In four groups of ten healthy adult subjects (five males and five females), two subjects were randomized to receive placebo and eight subjects to receive<jats:italic>trans<\/jats:italic>\u2010resveratrol 25, 50, 100 or 150 mg, six times\/day, for thirteen doses. Peak plasma concentrations of<jats:italic>trans<\/jats:italic>\u2010resveratrol were reached at 0.8\u20131.5 h postdose. Following the 13th dose of<jats:italic>trans<\/jats:italic>\u2010resveratrol 25, 50, 100 and 150 mg, mean peak plasma concentration (<jats:italic>C<\/jats:italic><jats:sub>max<\/jats:sub>) was 3.89, 7.39, 23.1 and 63.8 ng\/mL and mean area under the plasma concentration\u2013time curve (AUC<jats:sub>0\u2010\u03c4<\/jats:sub>) was 3.1, 11.2, 33.0 and 78.9 ng\u00b7h\/mL. Interindividual variability was high, with coefficients of variation &gt;40%.<jats:italic>Trans<\/jats:italic>\u2010resveratrol half\u2010life was 1\u20133 h following single\u2010doses and 2\u20135 h following repeated dosing. Trough (<jats:italic>C<\/jats:italic><jats:sub>min<\/jats:sub>) concentrations were \u2a871 ng\/mL following 25 and 50 mg, 3 ng\/mL following 100 mg and &lt;\u00a010 ng\/mL following 150 mg.<jats:italic>Trans\u2010<\/jats:italic>resveratrol pharmacokinetics showed circadian variation. Adverse events were mild in severity and similar between all groups. In conclusion, repeated administration was well\u2010tolerated but produced relatively low plasma concentrations of<jats:italic>trans<\/jats:italic>\u2010resveratrol, despite the high doses and short dosing interval used. Bioavailability was higher after morning administration.<\/jats:p>","DOI":"10.1002\/mnfr.200800177","type":"journal-article","created":{"date-parts":[[2009,2,4]],"date-time":"2009-02-04T13:41:46Z","timestamp":1233754906000},"source":"Crossref","is-referenced-by-count":344,"title":["Pharmacokinetic and safety profile of<i>trans<\/i>\u2010resveratrol in a rising multiple\u2010dose study in healthy volunteers"],"prefix":"10.1002","volume":"53","author":[{"given":"Luis","family":"Almeida","sequence":"first","affiliation":[]},{"given":"Manuel","family":"Vaz\u2010da\u2010Silva","sequence":"additional","affiliation":[]},{"given":"Am\u00edlcar","family":"Falc\u00e3o","sequence":"additional","affiliation":[]},{"given":"Eva","family":"Soares","sequence":"additional","affiliation":[]},{"given":"Raquel","family":"Costa","sequence":"additional","affiliation":[]},{"given":"Ana I.","family":"Loureiro","sequence":"additional","affiliation":[]},{"given":"Carlos","family":"Fernandes\u2010Lopes","sequence":"additional","affiliation":[]},{"given":"Jos\u00e9\u2010Francisco","family":"Rocha","sequence":"additional","affiliation":[]},{"given":"Teresa","family":"Nunes","sequence":"additional","affiliation":[]},{"given":"Lyndon","family":"Wright","sequence":"additional","affiliation":[]},{"given":"Patr\u00edcio","family":"Soares\u2010da\u2010Silva","sequence":"additional","affiliation":[]}],"member":"311","published-online":{"date-parts":[[2009,5,27]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.1002\/mnfr.200500022"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0024-3205(99)00410-5"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1089\/152308601317203567"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1530\/eje.0.1380619"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.2003.tb07534.x"},{"key":"e_1_2_1_7_2","first-page":"257","article-title":"Wine and tumors: Study of resveratrol","volume":"29","author":"Bruno R.","year":"2003","journal-title":"Drugs Exp. Clin. Res."},{"key":"e_1_2_1_8_2","first-page":"17","article-title":"Cancer prevention by resveratrol: in vitro and in vivo studies and the underlying mechanisms","volume":"23","author":"Aziz M. H.","year":"2003","journal-title":"Int. J. Oncol."},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.2174\/1568011033353443"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.2174\/138945006776359331"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.brainresrev.2006.04.004"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2006.12.036"},{"key":"e_1_2_1_13_2","first-page":"105","article-title":"Stimulation of endogenous adenosine release by oral administration of quercetin and resveratrol in man","volume":"25","author":"Blardi P.","year":"1999","journal-title":"Drugs Exp. Clin. Res."},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.EPI-07-0022"},{"key":"e_1_2_1_15_2","doi-asserted-by":"publisher","DOI":"10.1002\/mnfr.200700290"},{"key":"e_1_2_1_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0378-4347(01)00142-6"},{"key":"e_1_2_1_17_2","unstructured":"FDA\/CDER Guidance for Industry: Bioanalytical Method Validation 2001."},{"key":"e_1_2_1_18_2","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.104.000885"},{"key":"e_1_2_1_19_2","doi-asserted-by":"publisher","DOI":"10.1002\/mnfr.200500010"},{"key":"e_1_2_1_20_2","doi-asserted-by":"publisher","DOI":"10.5414\/CPP46564"},{"key":"e_1_2_1_21_2","doi-asserted-by":"publisher","DOI":"10.1002\/mnfr.200500002"},{"key":"e_1_2_1_22_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-199835020-00001"},{"key":"e_1_2_1_23_2","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.102.033340"},{"key":"e_1_2_1_24_2","first-page":"283","article-title":"Circadian rhythmic hepatic biliary flow, constituents, concentrations and excretory rates in patients after cholecystectomy","volume":"21","author":"Ho K. J.","year":"1994","journal-title":"Chronobiologia"},{"key":"e_1_2_1_25_2","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1016\/S0022-3565(25)39467-X","article-title":"Multiple\u2010dose lorazepam kinetics: Shuttling of lorazepam glucuronide between the circulation and the gut during day\u2010 and night\u2010time dosing intervals in response to feeding","volume":"267","author":"Chaudhary A.","year":"1993","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"e_1_2_1_26_2","first-page":"785","article-title":"Nebicapone (BIA 3\u2010202) pharmacokinetics following repeated administration to healthy subjects","volume":"63","author":"Maia J.","year":"2007","journal-title":"Br. J. Clin. Pharmacol."},{"key":"e_1_2_1_27_2","doi-asserted-by":"publisher","DOI":"10.1002\/jps.20156"}],"container-title":["Molecular Nutrition &amp; Food Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fmnfr.200800177","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/mnfr.200800177","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T11:12:15Z","timestamp":1738926735000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/mnfr.200800177"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,5]]},"references-count":26,"journal-issue":{"issue":"S1","published-print":{"date-parts":[[2009,5]]}},"alternative-id":["10.1002\/mnfr.200800177"],"URL":"https:\/\/doi.org\/10.1002\/mnfr.200800177","archive":["Portico"],"relation":{},"ISSN":["1613-4125","1613-4133"],"issn-type":[{"value":"1613-4125","type":"print"},{"value":"1613-4133","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,5]]}}}